27 completed, 10 terminated, 6 not yet recruiting, 5 withdrawn. 55 Phase 2, 11 Phase 3, 7 Phase 1.
Follow Sarcoidosis: new trials by email Literature Review of Sarcoidosis trials Research Report on Sarcoidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension | Phase 2 | Not yet recruiting | IRulya Therapeutics Inc. | 60 | 2026-12-01 | 2026-10-21 |
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-03 | 2026-11-09 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| A Trial of Baricitinib in Patients With Cardiac Sarcoidosis Baricitinib (LY3009104) 4 mg - Cardiac Sarcoidosis | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-04-01 | 2026-02-10 |
| Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Metformin, Cellulose - Sarcoidosis, Pulmonary | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2025-12-10 | 2025-02-11 | |
| A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis Oral Brepocitinib, Oral Placebo - Cutaneous Sarcoidosis | Phase 2 / Phase 3 | Recruiting | Priovant Therapeutics, Inc. | 168 | 2025-04-09 | 2026-11-03 |
| Tyrosine Kinase 2 (TYK2) for GA and CS Deucravacitinib - Sarcoidosis, Granuloma Annulare | Phase 2 | Withdrawn | Yale University | 2025-03-01 | 2025-04-29 | |
| Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis OATD-01, Placebo - Pulmonary Sarcoidosis | Phase 2 | Recruiting | Molecure S.A. | 96 | 2024-03-21 | 2026-10-08 |
| An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
| Feasibility of Semaglutide in Advanced Lung Disease Semaglutide Pen Injector - Obesity, Interstitial Lung Disease | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 8 | 2024-01-29 | 2026-04-21 |
| Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16 or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Active not recruiting | Xentria, Inc. | 32 | 2023-11-10 | 2026-10-02 |
| Janus Kinase Inhibition in Sarcoidosis Abrocitinib 200 mg - Sarcoidosis | Phase 2 | Completed | Yale University | 10 | 2023-06-01 | 2026-09-21 |
| A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis Namilumab, Placebo - Sarcoidosis, Pulmonary | Phase 2 | Terminated | Kinevant Sciences GmbH | 107 | 2022-08-31 | 2025-09-12 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis Namilumab - Sarcoidosis, Cardiac | Phase 2 | Terminated | Kinevant Sciences GmbH | 1 | 2022-08-23 | 2025-04-17 |
| Sirolimus in Cutaneous Sarcoidosis Sirolimus - Sarcoidosis, Cutaneous Sarcoidosis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2022-07-01 | 2022-07-14 |
| A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag Selexipag, Placebo - Sarcoidosis-associated Pulmonary Hypertension | Phase 2 | Terminated | Actelion | 10 | 2021-02-26 | 2024-05-08 |
| Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis 68GaNOTA-Anti-MMR-VHH2 - Solid Malignancy Located in the Head and Neck, Cancer | Phase 2 | Terminated | Universitair Ziekenhuis Brussel | 29 | 2021-01-26 | 2026-06-01 |
| Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis CMK389, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 62 | 2020-09-23 | 2025-04-13 |
Showing 20 of 55. Sign in to see all of them.
Sarcoidosis, Pulmonary (20) · Hypertension, Pulmonary (7) · Lung Diseases, Interstitial (5) · Pulmonary Fibrosis (3) · Granuloma (2) · Inflammation (2) · Lung Diseases (2) · Pulmonary Arterial Hypertension (2) · Autoimmune Diseases (1) · Behcet Syndrome (1) · Birdshot Chorioretinopathy (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1)
Hemic and Lymphatic Diseases (55) · Hypersensitivity (55) · Hypersensitivity, Delayed (55) · Immune System Diseases (55) · Lymphatic Diseases (55) · Lymphoproliferative Disorders (54) · Respiratory Tract Diseases (29) · Lung Diseases (27) · Lung Diseases, Interstitial (20) · Pathological Conditions, Signs and Symptoms (11) · Cardiovascular Diseases (10) · Vascular Diseases (10) · Pathologic Processes (8) · Hypertension (7)
Adalimumab (4) · Azithromycin (3) · Bosentan (2) · Ethambutol (2) · Levofloxacin (2) · Prednisone (2) · Rifampin (2) · namilumab (2) · 68Ga-DOTANOC (1) · Abatacept (1) · Adrenocorticotropic Hormone (1) · Atorvastatin (1) · Cellulose (1) · Cyclophosphamide (1) · Dapsone (1)
University of Cincinnati (4) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Novartis Pharmaceuticals (3) · Xentria, Inc. (3) · Albany Medical College (2) · Kinevant Sciences GmbH (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Stanford University (2) · University of Chicago (2) · Vanderbilt University (2) · Yale University (2) · Actelion (1) · Araim Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Bellerophon (1)
United States (42) · United Kingdom (9) · Germany (8) · Netherlands (6) · Belgium (4) · Denmark (4) · France (4) · Czechia (3) · Poland (3) · India (2) · Norway (2) · Spain (2) · Australia (1) · Austria (1) · Brazil (1)
Marc A Judson, MD (3) · Robert P Baughman, MD (3) · Ali Ataya, MD (1) · Daniel Doberer, MD, MSc (1) · Dariusz Stencel, MD (1) · Don C Rockey, MD (1) · Edward Parsley, DO (1) · Gennyne Walker (1) · Joseph Jorizzo, MD (1) · Joseph R Fontana, M.D. (1) · Juhani Knuuti, MD, PhD (1) · Matthew Baker, MD (1) · Matthew C Baker, MD, MS (1)
PMID 20926833, PMID 22004880, PMID 23863960, PMID 24177203, PMID 24488568, PMID 24751453, PMID 25034562, PMID 25428650, PMID 25594886, PMID 25638011, PMID 25811287, PMID 33089005, PMID 34029565, PMID 36356657, PMID 37471590, PMID 37854715, PMID 41819539
2009 (1), 2014 (1), 2018 (1), 2023 (1), 2025 (1), R01HL117074 (1)